Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background The biomarker model of Alzheimer’s disease (AD) hypothesizes a dynamic sequence of amyloidosis, neurodegeneration, and cognitive decline, as an individual progresses from preclinical AD to dementia. Despite supportive evidence from cross-sectional studies, verification with long-term within-individual data is needed. Methods Autosomal dominant AD (ADAD) mutation carriers, aged 21 years or older (no cognitive restrictions), were recruited from across the United States via referral by colleagues or ADAD families themselves. Sixteen individuals with mutations in PSEN1, PSEN2 or APP, aged 28 to 56, were assessed longitudinally every one to two years, between March 23, 2003 and August 1, 2014. Participants completed two to eight assessments (total=83), over a period of two to eleven years. We measured global amyloid-beta load with Pittsburgh Compound-B PET, posterior cortical metabolism with [18F]fluorodeoxyglucose PET, hippocampal volume (age-, and gender-corrected) with T1 MRI, verbal memory with 10-item delayed word recall, and general cognition with Mini Mental State Exam. We estimated overall biomarker trajectories across estimated years from symptom onset (EYO) using linear mixed models, and compared ADAD estimates to cross-sectional data from cognitively normal, older controls selected to be negative for amyloidosis, hypometabolism, and hippocampal atrophy. In seven individuals with the longest follow-up (seven/eight assessments spanning six to eleven years), we further examined the within-individual progression of amyloidosis, metabolism, hippocampal volume, and cognition, to identify progressive within-individual change in these markers (increase/decrease of greater than two Z-scores standardized to controls). Findings Significant differences in ADAD compared to controls (p<0·01) were detected in the following order: increased amyloidosis (−7.5 EYO), decreased metabolism (0 EYO), decreased hippocampal volume and verbal memory (+7.5 EYO), decreased general cognition (+10 EYO). Within-individual examination of AD markers found three individuals demonstrating active amyloidosis, without progressive neurodegeneration or cognitive decline. Two amyloid-positive individuals showed neither active amyloidosis, nor progressive neurodegeneration or cognitive decline. The two remaining amyloid-positive individuals showed progressive neurodegeneration and cognitive decline, without further progressive amyloidosis. Interpretation Our results strongly support amyloidosis as the earliest progressive component of the biomarker model in ADAD. Our within-individual examination further suggests three sequential phases across ADAD development: 1) active amyloidosis, 2) stable amyloid-positive and, 3) progressive neurodegeneration and cognitive decline, indicating that amyloid-beta accumulation is largely complete before progressive neurodegeneration and cognitive decline in our ADAD cohort, supporting efforts to target early amyloid-beta deposition as a means of secondary prevention in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationMedial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y. C., Waring, S. C., O'Brien, P. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., & Kokmen, E. (1997) · Neurology · doi:10.1212/wnl.49.3.786 · Cited by 1,128
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Welsh, K. A., Butters, N., Mohs, R. C., Beekly, D., Edland, S., Fillenbaum, G., & Heyman, A. (1994) · Neurology · doi:10.1212/wnl.44.4.609 · Cited by 951
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Cited by
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Self-citationBiomarker Changes during 20 Years Preceding Alzheimer’s Disease
Jia, J., Ning, Y., Chen, M., Wang, S., Yang, H., Li, F., Ding, J., Li, Y., Zhao, B., Lyu, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310168 · Cited by 455
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Rodriguez-Vieitez, E., Saint-Aubert, L., Carter, S. F., Almkvist, O., Farid, K., Schöll, M., Chiotis, K., Thordardottir, S., Graff, C., Wall, A., et al. (2016) · Brain · doi:10.1093/brain/awv404 · Cited by 300
Multimodal Attention-Based Deep Learning for Alzheimer’s Disease Diagnosis
Golovanevsky, M., Eickhoff, C., & Singh, R. (2022) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocac168 · Cited by 165
“Several studies focused on using time-series data to track the progression of the disease [17, 18, 23–25].”
Background
Metadata
- Authors
- Yau, W.-Y. W., Tudorascu, D. L., McDade, E. M., Ikonomovic, S., James, J. A., Minhas, D., Mowrey, W., Sheu, L. K., Snitz, B. E., Weissfeld, L., Gianaros, P. J., Aizenstein, H. J., Price, J. C., Mathis, C. A., Lopez, O. L., & Klunk, W. E.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 14
- Issue
- 8
- Pages
- 804-813
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2122280897
- Cited by
- 115
- References
- 16
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. https://app.cochat.ai/papers/10.1016/s1474-4422(15)00135-0
- The paper
- Yau, W.-Y. W., Tudorascu, D. L., McDade, E. M., Ikonomovic, S., James, J. A., Minhas, D., Mowrey, W., Sheu, L. K., Snitz, B. E., Weissfeld, L., Gianaros, P. J., Aizenstein, H. J., Price, J. C., Mathis, C. A., Lopez, O. L., & Klunk, W. E. (2015). Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(15)00135-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.